JSKN-008

N/A

Report date: 2025/03/24 16:52:45

Base Information

Drug NameJSKN-008
Drug Alias NameJSKN-008
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesAlphamab Oncology
China Registration ClassN/A

Develop Information

Active CompaniesAlphamab Oncology
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A